NPI: 1265503403 · BALTIMORE, MD 21215 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 11/10/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 11/10/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 11,542 | $23K |
| 2019 | 11,969 | $66K |
| 2020 | 7,057 | $102K |
| 2021 | 10,208 | $156K |
| 2022 | 7,073 | $124K |
| 2023 | 2,273 | $71K |
| 2024 | 101 | $3K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 10,083 | 1,200 | $461K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 22,138 | 1,220 | $69K |
| J1756 | Injection, iron sucrose, 1 mg | 2,595 | 712 | $7K |
| J1270 | Injection, doxercalciferol, 1 mcg | 7,931 | 733 | $5K |
| 83970 | 754 | 679 | $2K | |
| A4657 | Syringe, with or without needle, each | 1,936 | 1,313 | $790.99 |
| 82728 | 655 | 570 | $0.00 | |
| 83550 | 690 | 596 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 345 | 249 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 16 | 15 | $0.00 |
| 85041 | 1,299 | 1,117 | $0.00 | |
| 83540 | 703 | 596 | $0.00 | |
| 85048 | 1,078 | 942 | $0.00 |